Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
NMD Pharma is a small molecule drug discovery company that develops novel treatments of neuromuscular disorders.
Minervax is a biotechnology company developing a novel vaccine against Group B Streptococcus.
Pioneering the market introduction of powerful, autonomous, safe and eco-friendly water and air treatment solutions.
Clever Care Health Plan is a healthcare company that offers medicare advantage health plans to its members.
Horama develops gene therapies for rare inherited ocular and CNS (central nervous system) diseases.
AnaCardio is a clinical stage biopharmaceutical company developing novel drugs to treat heart failure.
Evosep develops new solutions to make clinical proteomics 100 times more robust and 10 times faster.
Alveus Therapeutics is a clinical-stage biotech company developing therapies for obesity and metabolic diseases.
Muna Therapeutics discovers and develops therapies that slow or stop neurodegenerative diseases such as alzheimer’s and parkinson's.
Bactolife is a biotechnology company that develops biological solutions to support gut health.
Praxis develops therapies for CNS disorders by leveraging genetic insights into neuronal imbalances, targeting rare to common conditions.
Revagenix is a biopharmaceutical company discovering and developing therapies to address medical needs.
Sidera Bio harness human genetics, that helps in transformative medicines for patients.
Exscientia is a pharmatech company that uses an end-to-end AI platform to design and discover new drugs.
Antag Therapeutics provides therapeutic peptides for the treatment of dietary-related metabolic diseases.
Biomason is a developer of a building materials technology that employs natural microorganisms to grow bio cement in ambient temperatures.
21st Bio has the potential to replace and improve a wide range of meals and materials with appealing sustainable bio-based alternatives.
SiteOne Therapeutics develops groundbreaking non-opioid treatments for acute, neuropathic, visceral, and musculoskeletal pain.
NorthSea Therapeutics is a clinical-stage biotech company developing first-in class, oral, structurally-engineered lipid therapeutics.
iECURE is a mutation-agnostic in vivo gene editing company striving to cure devastating diseases with high unmet needs.
Chromologics develops innovative natural food colorants.
Blue Planet Environmental Solution provides sustainable and socially inclusive end-to-end environmental solutions.
Arcellx develops engineered cell-based immunotherapies for the treatment of cancer and other serious diseases.
Booster Therapeutics is a biotech company that offers regulation of cellular homeostasis, as well as develops medicines for aging diseases.
Novo Holdings has invested in 216 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Novo Holdings's top investment sectors include Biotechnology, Medical, Health Care, Life Science, Pharmaceutical. The firm invests across 24 different industry categories.
Among tracked funding rounds, Praxis Precision Medicines received $575.0M in a Post-IPO Equity round. Novo Holdings's total known invested capital is $15.2B.
Novo Holdings's average investment size is $84.4M across its portfolio of 216 companies.
Recent Novo Holdings portfolio additions include NMD Pharma, Minervax, HPNow, Clever Care Health Plan Inc., Coave Therapeutics. These companies were founded in 2020 or later.